To learn more about ovarian cancer treatments, please visit [ Ссылка ]

Learn about MSK: [ Ссылка ]

CONNECT WITH MSK
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]

Request an appointment at MSK by calling 800-525-2225 or online at: [ Ссылка ]

Medical oncologist Katherine Bell-McGuinn describes a novel class of ovarian cancer therapies called PARP inhibitors. These drugs, which are in development at Memorial Sloan Kettering Cancer Center, are designed to block a protein called PARP that causes tumor cells to grow uncontrollably. (In normal cells, PARP helps repair damaged DNA.) This approach could help the 10% of patients who have deficiencies in another protein called BRCA, which is also involved in DNA repair, and whose cells therefore rely more heavily on PARP to repair DNA breaks within tumor cells.

{partial transcript}

As Carol mentioned, I will focus on PARP inhibitors, one of the new classes of therapies that have hit the ovarian cancer clinic in the last two-to-three years and share with you why we are trying to target this for a therapy for ovarian cancer. I’ll share with you some of the initial results we’ve seen in the laboratory and in patients as well as update you on what we are doing here and what clinical trials are available for our patients.

As part of running these studies, we do receive support here at Memorial Sloan Kettering from Astra Zeneca and BiPar, which are two of the companies that we are working with.

We are going to talk about the rationale for these agents. Why target PARP? What is PARP? What does it do in the cell?

We are also going to talk about which patients can benefit from these drugs, specifically BCR patients. We are also going to talk about laboratory models and clinical studies that have gone on. Finally, we are going to talk about where we are now, and where we are going.

свернуть